Invesco Biotechnology & Genome ETF is a ETF series of Invesco Exchange-Traded Fund Trust (series S000003026). Net assets $247.4M as of 2026-04-30. Index fund.
Showing 15 of 33 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Invesco Private Prime Fund | — | $27.0M | 1091.61% |
| United Therapeutics Corp. | — | $15.5M | 628.48% |
| Illumina, Inc. | — | $13.3M | 537.08% |
| Biogen Inc. | — | $12.5M | 505.18% |
| Incyte Corp. | — | $12.1M | 491.01% |
| Alnylam Pharmaceuticals, Inc. | — | $12.0M | 484.23% |
| Regeneron Pharmaceuticals, Inc. | — | $11.8M | 476.86% |
| Amgen Inc. | — | $11.7M | 471.00% |
| Gilead Sciences, Inc. | — | $11.4M | 461.54% |
| Invesco Private Government Fund | — | $10.4M | 420.12% |
| BioCryst Pharmaceuticals, Inc. | — | $8.5M | 341.93% |
| Catalyst Pharmaceuticals, Inc. | — | $8.2M | 330.34% |
| Arrowhead Pharmaceuticals, Inc. | — | $8.1M | 327.84% |
| Protagonist Therapeutics, Inc. | — | $8.0M | 321.72% |
| TG Therapeutics, Inc. | — | $7.8M | 314.52% |
| Report date | Net assets |
|---|---|
| 2026-04-30 | $247.4M |
| 2026-01-31 | $263.0M |
| 2025-10-31 | $234.1M |
| 2025-07-31 | $225.4M |
| 2025-04-30 | $221.3M |
| 2025-01-31 | $255.2M |
| 2024-10-31 | $257.1M |
| 2024-07-31 | $269.9M |